754143
Last Update Posted: 2019-08-02
Recruiting has ended
All Genders accepted | 18 Years-80 Years |
38 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
The purpose of this study is to evaluate the safety and tolerability of two dosing regimens of FG-3019 administered over 12 weeks in patients with diabetic nephropathy and proteinuria on background angiotensin converting enzyme inhibitor (ACEi) and/or angiotensin II receptor antagonist (ARB) therapy.
Eligibility
Relevant conditions:
Diabetes Mellitus
Diabetic Nephropathy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov